A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females
A phase I, open label, single-centre study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV -16/18 L1 VLP AS04 vaccine (GSK 580299, Cervarix TM), administered intramuscularly according to a 0, 1, 6-month schedule in healthy Chinese female subjects aged 15 - 45 years.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Infections, Papillomavirus
BIOLOGICAL: GSK580299 (Cervarixâ„¢ , HPV -16/18 L1 VLP AS04 vaccine)
Number of Subjects Reporting Serious Adverse Events, Serious adverse events are defined as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject., Throughout the study period (up to Month 7)|Number of Subjects Reporting Solicited Local Symptoms, Solicited local symptoms assessed include pain, redness and swelling., During the 7-day (Day 0-6) period following each vaccination|Number of Subjects Reporting Solicited General Symptoms, Solicited general symptoms assessed include arthralgia, fatigue, fever, gastrointestinal symptoms, headache, myalgia, rash, and urticaria., During the 7-day (Day 0-6) period following each vaccination|Number of Subjects Reporting Unsolicited Adverse Events (AEs), An unsolicited adverse event is defined as any adverse event (AE) reported in addition to those solicited during the clinical study. Also any "solicited" symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event., Within 30 days (Day 0-29) after any vaccination|Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Hematological Parameters, Hematological and biochemical parameters assessed in blood samples include alanine aminotransferase (ALT), basophils, creatinine, eosinophils, hematocrit, lymphocytes, monocytes, neutrophils, platelets, red blood cell, and white blood cells.

Abnormalities reported include values outside the normal ranges: values higher than normal are designated as "Above" and values lower than normal as "Below"., At Month 0 and Month 7|Number of Subjects Reporting Medically Significant Adverse Events, Medically significant AEs were defined as AEs prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that were not related to common diseases. Common diseases include: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities and injury., Throughout the study period (up to Month7)
The rationale for the protocol posting amendment was to change the study population from 18-35 to 15-45 years and to allow subjects who were administered routine vaccines e.g. Hepatitis A\&B vaccines, meningococcal vaccines, Tetanus vaccine, Diphteria Tetanus Pertussis etc. up to 8 days before each HPV dose.